Prostatype Genomics AB (OSTO:PROGEN) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

What is Prostatype Genomics AB LT-Debt-to-Total-Asset?

Prostatype Genomics AB OSTO:PROGEN -8.33% 25 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Prostatype Genomics AB's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Prostatype Genomics AB's long-term debt to total assets ratio stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Prostatype Genomics AB (OSTO:PROGEN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Prostatype Genomics AB LT-Debt-to-Total-Asset Related Terms

Prostatype Genomics AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB LT-Debt-to-Total-Asset Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.00

Prostatype Genomics AB Semi-Annual Data
	Jun18	Jun19	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial								0.00	0.00	0.00	0.00	0.00

25GF Score

Prostatype Genomics AB OSTO:PROGEN

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Prostatype Genomics AB LT-Debt-to-Total-Asset Calculation

Prostatype Genomics AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	50.862
	=	0.00

Prostatype Genomics AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0	/	50.862
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Prostatype Genomics AB (OSTO:PROGEN) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Prostatype Genomics AB and its competitors.

Is Prostatype Genomics AB's LT-Debt-to-Total-Asset too high?

Prostatype Genomics AB's current LT-Debt-to-Total-Asset is 0.00. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Prostatype Genomics AB's LT-Debt-to-Total-Asset compare to TMO and DHR?

Prostatype Genomics AB's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?

A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Prostatype Genomics AB stock overvalued right now?

Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.33 — trading 200% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.33 is trading 200% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

LT-Debt-to-Total-Asset: 0.00
GF Value™: kr0.11 vs. price of kr0.33 (200% above fair value)
GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies XSAT:SPERM NGM:LEVBIO NGM:ATANA XSAT:GEAN NGM:LUMITO OSTO:IDLDX OSTO:IMMNOV TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN MTD DGX LH

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52

Website https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

25GF Score

Get the complete analysis for OSTO:PROGEN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.33

Price

kr0.11

GF Value

View OSTO:PROGEN Analysis

See LT-Debt-to-Total-Asset data for all stocks →